SecBot SecBot
PRESS-RELEASE ·Filed Nov 12, 2026

REGN

Regeneron Pharmaceuticals, Inc.
BULLISH
Impact 5/10
Horizonmonths Processed3d 15h ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

Phase 3 trial initiation in H1 2027 is the next catalyst. Monitor for regulatory feedback and any competitive developments in the POTS space. The Phase 2 data are early but address a high unmet need.

DirectionBullish
Confidencemedium
Horizonmonths

baloncibart

● Neutral Named in this press release
Impact
Phase
Phase 2
Time to market
At least 4-6 years away, if successful. Both Phase 2 trials are complete but results have not been disclosed, and no Phase 3 trials have been registered. The drug would need positive Phase 2 data, Phase 3 trials, and FDA review before any potential approval.
Next catalyst
None dated

What to watchWatch for potential disclosure of Phase 2 topline results from either the POTS (PINNACLE) or sepsis (ESTELLA) trial, possibly at a future medical conference or in Regeneron's quarterly earnings materials. Positive results could support advancement to Phase 3, but given Regeneron's size and pipeline breadth, even a clear readout is unlikely to move the stock more than a few percent.

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+1
Entry
$955.47
T+0 close · Nov 12, 2026 · via day close
Latest settled
−0.32%
T+1 · $952.40
Vs SPY
+1.59%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $955.47entry
  2. T+1 · 16h ago −0.32%α +1.59% · $952.40
  3. T+5 · in 3d Pending
  4. T+20 · in 27d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Regeneron announced positive Phase 2 PINNACLE trial results for baloncibart in POTS, showing a single 450 mg dose reduced heart rate upon standing and improved symptoms through four weeks. A potentially pivotal Phase 3 trial is planned for the first half of 2027. No FDA-approved treatments currently exist for POTS, which affects 500,000 to several million people in the U.S.

Key Facts

  • Phase 2 PINNACLE trial evaluated single subcutaneous doses of baloncibart 150 mg (n=27) or 450 mg (n=28) vs placebo (n=27) in POTS patients.
  • Baloncibart 450 mg reduced DeltaHR vs placebo at day 8 with LS mean difference of -11.4 bpm (nominal p=0.0007) and at day 29 with -7.4 bpm (nominal p=0.0124).
  • Baloncibart 450 mg improved orthostatic symptoms, physical functioning, and activities of daily living vs placebo at day 29 per LWPQ.
  • No FDA-approved treatments exist for POTS; potentially pivotal Phase 3 trial planned for first half of 2027.
  • Single doses up to 450 mg were generally well tolerated; TEAEs mostly mild/moderate, no TEAE led to discontinuation.

Financial Impact

No financial figures stated; POTS affects 500K to several million U.S. patients with no approved therapies, representing a large potential market for Regeneron ($99.2B market cap).

revenue

Risk Factors

  • Phase 3 trial may fail to replicate Phase 2 results; safety and efficacy not yet evaluated by any regulatory authority.
  • POTS diagnosis and market size estimates are uncertain; commercial adoption depends on regulatory approval and reimbursement.
  • Competing therapies may emerge before baloncibart reaches market.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
72% bullish (36 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3402308

Track record

53 reports on REGN

Performance horizon

11 of 17 bullish or bearish reports moved the stock their way by T+20. Best: +31.76% at T+20 after the Oct 6, 2026 report. 17 of 20 went positive at some point.

Filters
  1. Nov 16, 2026today 144 Neutral 2/10 Entry $951.23 Now $952.40 +0.12% settles Dec 16
  2. Nov 16, 2026today 144 Neutral 2/10 Entry $948.00 Now $952.40 +0.46% settles Dec 16
  3. Nov 12, 20264d ago Press Release Bullish 5/10 Viewing Entry $955.47 Now $952.40 −0.32% settles Dec 14
  4. Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
  5. Nov 5, 202611d ago Insider Cluster Neutral 3/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
  6. Nov 4, 202612d ago 144 Neutral 1/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
  7. Nov 4, 202612d ago 144 Neutral 2/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
  8. Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
  9. Nov 3, 202613d ago 144 Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
  10. Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
Showing 10 of 53

US Market Status

Market Closed · Opens Wed (10h 4m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026